|Bid||0.780 x 0|
|Ask||0.820 x 0|
|Day's Range||0.800 - 0.800|
|52 Week Range||0.720 - 1.100|
|Beta (5Y Monthly)||0.79|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jun 28, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Growth Achieved in Revenue and Business Diversification Synergies from Each Business Segment, Steady Expansion in New Biomedical Businesses HONG KONG , June 28, 2019 /PRNewswire/ -- Golden Meditech Holdings ...
HONG KONG, May 24, 2019 /PRNewswire/ -- Golden Meditech Holdings Limited (SEHK stock code: 00801) ("Golden Meditech" or the "Company", together with its subsidiaries, the "Group"), a leading integrated healthcare enterprise in China, announced that, Mr Kam Yuen ("Mr Kam") and Mr Kong Kam Yu ("Mr Kong"), executive directors of the Company, Ms Zheng Ting ("Ms Zheng"), non-executive director, Professor Gu Qiao and Professor Cao Gang, independent non-executive directors, voluntarily resigned due to personal reasons.
HONG KONG, April 17, 2019 /PRNewswire/ -- Golden Meditech Holdings Limited (SEHK stock code: 00801) ("Golden Meditech"), a leading integrated healthcare enterprise in China, announced that it has formed a collaboration with the Department of Biology of Hong Kong Baptist University ("HKBU") to conduct in-depth research in the area of cell therapy, particularly treating neurodegenerative diseases with stem cells. Neurodegenerative diseases are mainly caused by the death or degeneration of nerve cells in the brain. According to statistics published in 2015, over 100 million people worldwide suffer from neurodegenerative diseases.